Predictive value of prognostic nutritional index combined with NLR and PLR in all-cause mortality of patients with peritoneal dialysis

doi:10.11958/20221230

Abstract

CLC Number:

R459.51

Figures/Tables 7

References 19

[1]	黄芃菲, 卢成志. 小剂量沙库巴曲缬沙坦用于治疗心力衰竭合并慢性肾脏病1-3期患者的研究[J]. 天津医药, 2022, 50(9):993-997.
	HUANG P F, LU C Z. Efficacy and safety of low-dose sacubitril/valsartan in patients with heart failure and stage 1-3 chronic kidney disease[J]. Tianjin Med J, 2022, 50(9):993-997. doi:10.11958/20212073.
[2]	CHUASUWAN A, POORIPUSSARAKUL S, THAKKINSTIAN A, et al. Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis:A systematic review and meta-analysis[J]. Health Qual Life Outcomes, 2020, 18(1):191. doi:10.1186/s12955-020-01449-2.
[3]	PONCE D, BRABO A M, BALBI A L. Urgent start peritoneal dialysis[J]. Curr Opin Nephrol Hypertens, 2018, 27(6):478-486. doi:10.1097/MNH.0000000000000451.
[4]	SAKAMOTO T, YAGYU T, UCHINAKA E, et al. The prognostic significance of combined geriatric nutritional risk index and psoas muscle volume in older patients with pancreatic cancer[J]. BMC Cancer, 2021, 21(1):342. doi:10.1186/s12885-021-08094-y.
[5]	ITOH S, TSUJITA E, FUKUZAWA K, et al. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma:A multi-institutional retrospective study[J]. Pancreatology, 2021, 21(7):1356-1363. doi:10.1016/j.pan.2021.08.003.
[6]	闫可, 魏菀怡, 杜星语, 等. 预后营养指数对老年食管癌患者根治性放疗后长期生存的预测价值[J]. 天津医药, 2021, 49(8):861-865.
	YAN K, WEI W Y, DU X Y, et al. The predictive value of prognostic nutritional index for long-term survival after radical radiotherapy in elderly patients with esophageal cancer[J]. Tianjin Med J, 2021, 49(8):861-865. doi:10.11958/20210143.
[7]	BISCH S, NELSON G, ALTMAN A. Impact of nutrition on enhanced recovery after surgery (eras) in gynecologic oncology[J]. Nutrients, 2019, 11(5):1088. doi:10.3390/nu11051088.
[8]	YANG Y, ZHOU H, ZHANG P, et al. Evaluation of objective nutritional indexes as predictors of worse outcomes in peritoneal dialysis patients[J]. Nutrition, 2020,79-80:110963. doi:10.1016/j.nut.2020.110963.
[9]	HE P, HE L J, HUANG C, et al. Neutrophil-to-lymphocyte ratio and treatment failure in peritoneal dialysis-associated peritonitis[J]. Front Med (Lausanne), 2021, 8:699502. doi:10.3389/fmed.2021.699502.
[10]	ZHANG L, NIE Y, GUO M, et al. Neutrophil to lymphocyte ratio as a predictor of long-term outcome in peritoneal dialysis patients:A 5-year cohort study[J]. Blood Purif, 2021, 50(6):772-778. doi:10.1159/000510552.
[11]	KIEBALO T, HOLOTKA J, HABURA I, et al. Nutritional status in peritoneal dialysis:Nutritional guidelines,adequacy and the management of malnutrition[J]. Nutrients, 2020, 12(6):1715. doi:10.3390/nu12061715.
[12]	XU X, LI Z, CHEN Y, et al. Dietary fibre and mortality risk in patients on peritoneal dialysis[J]. Br J Nutr, 2019, 122(9):996-1005. doi:10.1017/S0007114519001764.
[13]	WINCHESTER J F, HARBORD N, AUDIA P, et al. The 2006 K/DOQI guidelines for peritoneal dialysis adequacy are not adequate[J]. Blood Purif, 2007, 25(1):103-105. doi:10.1159/000096405.
[14]	YANG Y, XU Y, ZHANG P, et al. Predictive value of objective nutritional indexes in technique failure in peritoneal dialysis patients[J]. J Ren Nutr, 2021, 32(5):605-612. doi:10.1053/j.jrn.2021.09.005.
[15]	DENT E, HOOGENDIJK E O, VISVANATHAN R, et al. Malnutrition screening and assessment in hospitalised older people:A review[J]. J Nutr Health Aging, 2019, 23(5):431-441. doi:10.1007/s12603-019-1176-z.
[16]	USTA M, ERSOY A, AYAR Y, et al. The relationship between lymphocyte subsets,nutritional status and tuberculin reactivity in continuous ambulatory peritoneal dialysis and hemodialysis patients[J]. Int Urol Nephrol, 2020, 52(6):1167-1172. doi:10.1007/s11255-020-02467-1.
[17]	祝旭颖, 蔡宏, 张伟明, 等. 中性粒淋巴细胞比在评估维持性血液透析患者腹主动脉钙化及预后中的作用[J]. 中国血液净化, 2021, 20(12):814-818,845.
	ZHU X Y, CAI H, ZHANG W M, et al. Role of neutrophil-lymphocyte ratio in evaluating abdominal aortic calcification and prognosis in main-tenance hemodialysis patients[J]. Chinese Journal of Blood Purification, 2021, 20(12):814-818,845. doi:10.3969/j.issn.1671-4091.2021.12.006.
[18]	CONDADO J F, JUNPAPARP P, BINONGO J N, et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can risk stratify patients in transcatheter aortic-valve replacement(TAVR)[J]. Int J Cardiol, 2016, 223:444-449. doi:10.1016/j.ijcard.2016.08.260.
[19]	LISOWSKA K A, PINDEL M, PIETRUCZUK K, et al. The influence of a single hemodialysis procedure on human T lymphocytes[J]. Sci Rep, 2019, 9(1):5041. doi:10.1038/s41598-019-41619-x.

组别	n					年龄（岁）					性别（男/女）			腹透时间（月）					高血压				糖尿病
存活组	118					48.34±13.69					65/53			60.67±25.55					75（63.6）				19（16.1）
死亡组	71					59.44±12.43					47/24			34.51±21.34					68（95.8）				23（32.4）
t、χ²或Z						5.587^＊＊					2.267			7.240^＊＊					24.982^＊＊				6.808^＊＊
组别		TG （mmol/L）					TC （mmol/L）					HDL-C （mmol/L）					LDL-C （mmol/L）					UA （μmol/L）
存活组		1.47±0.70					4.82±1.35					1.20±0.31					2.82±1.02					431.47±139.78
死亡组		1.60±0.75					5.00±1.43					1.22±0.25					3.07±1.01					459.15±166.84
t、χ²或Z		1.222					0.844					0.380					1.632					1.225
组别				K⁺（mmol/L）					Na⁺（mmol/L）						Cl^-（mmol/L）					Ca²⁺（mmol/L）
存活组				4.50±0.89					140.92±3.40						101.88±10.47					1.95（1.77，2.09）
死亡组				4.82±0.96					140.15±3.22						102.48±9.23					2.00（1.82，2.13）
t、χ²或Z				2.351					1.536						0.399					1.412
组别			Mg²⁺ （mmol/L）					P³⁺ （mmol/L）					TP （g/L）					ALB （g/L）						GLU （mmol/L）
存活组			0.95±0.20					1.80±0.52					57.68±7.80					33.56±5.83						5.57±3.70
死亡组			0.94±0.21					1.69±0.52					57.41±9.73					32.64±4.90						5.91±3.11
t、χ²或Z			0.203					1.378					0.208					1.099						0.632
组别					HGB（g/L）					NLR						PLR					PNI
存活组					83.03±17.46					3.73±2.24						137.61±34.68					54.63±13.40
死亡组					79.21±19.50					4.97±2.22						168.26±52.58					43.28±12.91
t、χ²或Z					1.395					3.711^＊＊						4.826^＊＊					5.713^＊＊

组别	n					年龄（岁）					性别（男/女）			腹透时间（月）					高血压				糖尿病
存活组	118					48.34±13.69					65/53			60.67±25.55					75（63.6）				19（16.1）
死亡组	71					59.44±12.43					47/24			34.51±21.34					68（95.8）				23（32.4）
t、χ²或Z						5.587^＊＊					2.267			7.240^＊＊					24.982^＊＊				6.808^＊＊
组别		TG （mmol/L）					TC （mmol/L）					HDL-C （mmol/L）					LDL-C （mmol/L）					UA （μmol/L）
存活组		1.47±0.70					4.82±1.35					1.20±0.31					2.82±1.02					431.47±139.78
死亡组		1.60±0.75					5.00±1.43					1.22±0.25					3.07±1.01					459.15±166.84
t、χ²或Z		1.222					0.844					0.380					1.632					1.225
组别				K⁺（mmol/L）					Na⁺（mmol/L）						Cl^-（mmol/L）					Ca²⁺（mmol/L）
存活组				4.50±0.89					140.92±3.40						101.88±10.47					1.95（1.77，2.09）
死亡组				4.82±0.96					140.15±3.22						102.48±9.23					2.00（1.82，2.13）
t、χ²或Z				2.351					1.536						0.399					1.412
组别			Mg²⁺ （mmol/L）					P³⁺ （mmol/L）					TP （g/L）					ALB （g/L）						GLU （mmol/L）
存活组			0.95±0.20					1.80±0.52					57.68±7.80					33.56±5.83						5.57±3.70
死亡组			0.94±0.21					1.69±0.52					57.41±9.73					32.64±4.90						5.91±3.11
t、χ²或Z			0.203					1.378					0.208					1.099						0.632
组别					HGB（g/L）					NLR						PLR					PNI
存活组					83.03±17.46					3.73±2.24						137.61±34.68					54.63±13.40
死亡组					79.21±19.50					4.97±2.22						168.26±52.58					43.28±12.91
t、χ²或Z					1.395					3.711^＊＊						4.826^＊＊					5.713^＊＊

指标	AUC（95%CI）	敏感度（%）	特异度（%）	约登指数	最佳临界值	Z
NLR	0.684（0.612~0.749）	57.75	79.66	0.374	4.91	4.553^＊＊
PLR	0.689（0.618~0.754）	67.61	68.64	0.362	152.92	4.481^＊＊
PNI	0.729（0.660~0.791）	57.75	80.51	0.383	43.74	6.047^＊＊
联合指标	0.842（0.782~0.891）	87.32	68.64	0.560	-	12.330^＊＊

指标	AUC（95%CI）	敏感度（%）	特异度（%）	约登指数	最佳临界值	Z
NLR	0.684（0.612~0.749）	57.75	79.66	0.374	4.91	4.553^＊＊
PLR	0.689（0.618~0.754）	67.61	68.64	0.362	152.92	4.481^＊＊
PNI	0.729（0.660~0.791）	57.75	80.51	0.383	43.74	6.047^＊＊
联合指标	0.842（0.782~0.891）	87.32	68.64	0.560	-	12.330^＊＊

指标	β	SE	Wald χ²	P	HR	HR 95%CI
年龄	0.027	0.009	8.631	0.003	1.028	1.009~1.047
高血压	0.878	0.265	10.952	0.001	2.406	1.430~4.046
糖尿病	0.611	0.270	5.110	0.024	1.843	1.085~3.131
PNI	1.030	0.255	16.371	<0.001	2.802	1.701~4.616
PLR	1.046	0.271	14.847	<0.001	2.846	1.672~4.844
NLR	0.820	0.256	10.252	0.001	2.271	1.375~3.753

Predictive value of prognostic nutritional index combined with NLR and PLR in all-cause mortality of patients with peritoneal dialysis

Cite this article

RichHTML

PDF (PC)

Knowledge

Abstract

share this article

Figures/Tables 7

References 19

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LI Min, GONG Jian, WU Weiwei, LIU Qiao. Research progress on the role of Nrf2/HO-1 pathway in psoriasis [J]. Tianjin Medical Journal, 2024, 52(5): 552-556.
[2]	WANG Funing, DAI Huibo, SHAN Yun, YU Manshu, SHENG Meixiao. Study on the effect and mechanism of bone marrow mesenchymal stem cells on apoptosis of peritoneal mesothelial cells [J]. Tianjin Medical Journal, 2024, 52(2): 113-118.
[3]	YU Hong, YANG Chaodong, LIU dan. The relationship between ALT/ALP ratio, PLR and hepatic injury in elderly patients with septic shock [J]. Tianjin Medical Journal, 2024, 52(11): 1211-1215.
[4]	YANG Kai, HOU Dingcong, DUAN Shaoxian, BI Yi, XIE Yan, ZHANG Li, JIANG Wentao. Predictive values of PNI, LMR and MELD for early lung infection after liver transplantation [J]. Tianjin Medical Journal, 2024, 52(10): 1041-1045.
[5]	HE Miao, PENG Rong, TIAN Jinshan, LIU Xuan, DENG Lei, WU Qian. Relationship between perioperative nutrition risk and venous thromboembolism in patients with hip fracture [J]. Tianjin Medical Journal, 2024, 52(1): 97-101.
[6]	ZHAO Caiyun, HUA Shaofang. Clinical analysis and prediction of intrauterine fetal death in late trimester of pregnancy [J]. Tianjin Medical Journal, 2023, 51(4): 436-440.
[7]	LYU Chaoyang, HUANG Ting, XU Zaige, LIU Huishuang, YANG Yingjun, LI Zhenzhen, AO Wen. Impact of LncRNA TUG1 on high glucose-induced cardiomyocyte apoptosis by regulating the miR-181b-5p/PDCD4 axis [J]. Tianjin Medical Journal, 2023, 51(12): 1281-1287.
[8]	GUAN Guanghui, PU Qinhua, QIAN Hebu. Correlation between serum levels of MMP-13, VASH-1 and prognosis in patients with sepsis complicated with acute kidney injury [J]. Tianjin Medical Journal, 2023, 51(12): 1360-1264.
[9]	WANG Jinxiang, XU Guowu, WANG Tailan, WANG Le, JIN Heng, CHAI Yanfen. Effects of mild hypothermia treatment on the immune and neurological function in a swine model of extracorporeal cardiopulmonary resuscitation after cardiac arrest [J]. Tianjin Medical Journal, 2023, 51(10): 1076-1079.
[10]	LI Qiuchang, YAN Shunchang, MENG Yazhen, GU Yunxia, NING Qiaoming, LI Na, WANG Zhihua. Neuroprotective effects of dexmedetomidine on intracerebral hemorrhage of rats by Nrf2-GPX4 mediated iron death pathway [J]. Tianjin Medical Journal, 2022, 50(8): 817-821.
[11]	JI Hui, ZHOU Linling, YU Lan, JIANG Wei. Construction and validation of the nomogram predictive model for recurrence risk after primary meningioma resection [J]. Tianjin Medical Journal, 2022, 50(8): 863-867.
[12]	WANG Gang, WANG Qiong, JIANG Xin, ZHENG Jing. Correlation between miR-155 and PDCD4 expression in peripheral blood of infants with respiratory syncytial virus bronchiolitis [J]. Tianjin Medical Journal, 2022, 50(7): 757-761.
[13]	CHEN Yu, SU Jianjun, HAN Yun, LI Ying, ZHANG Lunmin, YANG Yi, HUANG Bo△. Study on the protective effect of dimethyl fumarate on myocardial ischemia/reperfusion injury by regulating the iron death pathway mediated by Nrf2-GPX4 in rats [J]. Tianjin Medical Journal, 2022, 50(6): 601-607.
[14]	WANG Xiaojie, LI Yuanyuan, LI Xueshan△. Relationship between preprotein invertase subtilisin 9 and recent adverse cardiovascular events in elderly patients with chronic heart failure [J]. Tianjin Medical Journal, 2022, 50(6): 618-622.
[15]	CHENG Ran, WEI Feng△, ZHANG Yuan, LIU Meilan, HE Jia. The inhibitory effect of 5-aza-2'-deoxycytidine on xenograft tumor of human thyroid carcinoma in nude mice and its mechanism [J]. Tianjin Medical Journal, 2022, 50(5): 476-481.